微小RNA在胶质瘤中的作用及机制研究进展

doi:10.3969/j.issn.1673-8640.2016.010.018

检验医学 ›› 2016, Vol. 31 ›› Issue (10): 917-921.DOI: 10.3969/j.issn.1673-8640.2016.010.018

微小RNA在胶质瘤中的作用及机制研究进展

陈秋丹¹, 林勇²

1. 上海市静安区中心医院复旦大学附属华山医院静安分院中心实验室,上海 200040
2. 上海市静安区中心医院复旦大学附属华山医院静安分院检验科,上海 200040

收稿日期:2015-09-05 出版日期:2016-10-20 发布日期:2016-11-01
作者简介:null
作者简介：陈秋丹,女,1988年生,硕士,技师,主要从事肿瘤分子病理学机制研究。

通讯作者：林勇,联系电话：021-61578271。
基金资助:
上海市卫生和计划生育委员会青年项目（20164Y0128）

Research progress on microRNAs in glioma

CHEN Qiudan¹, LIN Yong²

[1. Central Laboratory,Jing'an District Centre Hospital of Shanghai/Huashan Hospital Affiliated to Fudan University （Jing'an Branch）,Shanghai 200040,China
2. Department of Clinical Laboratory,Jing'an District Centre Hospital of Shanghai/Huashan Hospital Affiliated to Fudan University （Jing'an Branch）,Shanghai 200040,China]

Received:2015-09-05 Online:2016-10-20 Published:2016-11-01

摘要/Abstract

摘要：

胶质瘤是中枢神经系统中最常见的高致死率恶性肿瘤。微小RNA（miRNA）通过相关靶点调节下游信号通路,在胶质瘤中起着重要作用。因此,深入了解miRNA在胶质瘤中的作用及机制将为miRNA今后作为临床诊疗指标提供了新的思路和理论依据。

关键词: 微小RNA, 胶质瘤, 生物标志物

Abstract:

Glioma is a common malignant tumor in central nervous system with a high lethality. MicroRNAs are known to play vital roles in glioma through regulating the downstream signaling pathways via targets. Therefore,a deep understanding on the roles of microRNAs may provide new insights and theoretical reference for the diagnosis and treatment of glioma in the future.

Key words: MicroRNAs, Glioma, Biomarkers

中图分类号:

R446.1

陈秋丹, 林勇. 微小RNA在胶质瘤中的作用及机制研究进展[J]. 检验医学, 2016, 31(10): 917-921.

CHEN Qiudan, LIN Yong. Research progress on microRNAs in glioma[J]. Laboratory Medicine, 2016, 31(10): 917-921.

图/表 1

参考文献 30

[1]	STUPP R,MASON WP,VAN DEN BENT MJ,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med,2005,352(10):987-996.
[2]	CAI X,HAGEDORN CH,CULLEN BR.Human microRNAs are processed from capped,polyadenylated transcripts that can also function as mRNAs[J]. RNA,2004,10(12):1957-1966.
[3]	LEE Y,AHN C,HAN J,et al.The nuclear RNase Ⅲ Drosha initiates microRNA processing[J]. Nature,2003,425(6956):415-419.
[4]	BOHNSACK MT,CZAPLINSKI K,GORLICH D.Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs[J]. RNA,2004,10(2):185-191.
[5]	HUTVÁQNER G,MCLACHLAN J,PASQUINELLI AE,et al. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA[J]. Science,2001,293(5531):834-838.
[6]	SHI Z,CHEN Q,LI C,et al.MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras[J]. Neuro Oncol,2014,16(10):1341-1353.
[7]	LU SH,JIANG XJ,XIAO GL,et al.MiR-124a restoration inhibits glioma cell proliferation and invasion by suppressing IQGAP1 and β-catenin[J]. Oncol Rep,2014,32(5):2104-2110.
[8]	AN L,LIU Y,WU A,et al.microRNA-124 inhibits migration and invasion by down-regulating ROCK1 in glioma[J]. PLoS One,2013,8(7):e69478.
[9]	LV Z,YANG L.MiR-124 inhibits the growth of glioblastoma through the downregulation of SOS1[J]. Mol Med Rep,2013,8(2):345-349.
[10]	ZHAO WH,WU SQ,ZHANG YD.Downregulation of miR-124 promotes the growth and invasiveness of glioblastoma cells involving upregulation of PPP1R13L[J]. Int J Mol Med,2013,32(1):101-107.
[11]	DENG X,MA L,WU M,et al.miR-124 radiosensitizes human glioma cells by targeting CDK4[J]. J Neurooncol,2013,114(3):263-274.
[12]	WEI J,WANG F,KONG LY,et al.miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma[J]. Cancer Res,2013,73(13):3913-3926.
[13]	CHEN T,WANG XY,LI C,et al.Downregulation of microRNA-124 predicts poor prognosis in glioma patients[J]. Neurol Sci,2015,36(1):131-135.
[14]	WANG L,SHI ZM,JIANG CF,et al.MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma[J]. Oncotarget,2014,5(14):5416-5427.
[15]	ZHAO S,LIU H,LIU Y,et al.miR-143 inhibits glycolysis and depletes stemness of glioblastoma stem-like cells[J]. Cancer Lett,2013,333(2):253-260.
[16]	ZHANG Y,CHAO T,LI R,et al.MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a[J]. J Mol Med (Berl),2009,87(1):43-51.
[17]	GODLEWSKI J,NOWICKI MO,BRONISZ A,et al.Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal[J]. Cancer Res,2008,68(22):9125-9130.
[18]	SHI ZM,WANG J,YAN Z,et al.MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1[J]. PLoS One,2012,7(3):e32709.
[19]	DONG Q,CAI N,TAO T,et al.An axis involving SNAI1,microRNA-128 and SP1 modulates glioma progression[J]. PLoS One,2014,9(6):e98651.
[20]	LIN L,CHEN X,PENG X,et al.MicroRNA-128 promotes cell-cell adhesion in U87 glioma cells via regulation of EphB2[J]. Oncol Rep,2013,30(3):1239-1248.
[21]	PERUZZI P,BRONISZ A,NOWICKI MO,et al.MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells[J]. Neuro Oncol,2013,15(9):1212-1224.
[22]	SUN J,LIAO K,WU X,et al.Serum microRNA-128 as a biomarker for diagnosis of glioma[J]. Int J Clin Exp Med,2015,8(1):456-463.
[23]	GUO P,NIE Q,LAN J,et al.C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells[J]. Biochem Biophys Res Commun,2013,441(1):186-190.
[24]	QIAN X,ZHAO P,LI W,et al.MicroRNA-26a promotes tumor growth and angiogenesis in glioma by directly targeting prohibitin[J]. CNS Neurosci Ther,2013,19(10):804-812.
[25]	GUO P,LAN J,GE J,et al.MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated[J]. Exp Cell Res,2014,320(2):200-208.
[26]	YANG CH,YUE J,PFEFFER SR,et al.MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3(IGFBP3)[J]. J Biol Chem,2014,289(36):25079-25087.
[27]	YANG CH,PFEFFER SR,SIMS M,et al.The oncogenic microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesis[J]. J Biol Chem,2015,290(10):6037-6046.
[28]	CHAO TF,XIONG HH,LIU W,et al.MiR-21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and hMSH2[J]. J Huazhong Univ Sci Technolog Med Sci,2013,33(4):525-529.
[29]	ZHANG KL,HAN L,CHEN LY,et al.Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas[J]. Cancer Lett,2014,342(1):139-149.
[30]	LAKOMY R,SANA J,HANKEOVA S,et al.MiR-195,miR-196b,miR-181c,miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients[J]. Cancer Sci,2011,102(12):2186-2190.

miRNA	变化	相关靶点	功能	参考文献
miR-124	下调	RRAS、NRAS、IQGAP1、ROCK1、 SOS1、CDK4、STAT3、PPP1R13L	抑制肿瘤细胞增殖、迁移侵袭;增加药物敏感性和放疗敏感性;预后	[6-13]
miR-143	下调	NRAS、hexokinase 2	抑制肿瘤细胞增殖、迁移侵袭;增加药物敏感性;抑制糖酵解	[14-15]
miR-128	下调	P70S6K1、E2F3a、BMI1、SP1、 EphB2、SUZ12	抑制增殖和自我更新;诱导凋亡;抑制血管生成;阻滞细胞周期;降低辐射耐受;早期诊断	[16-22]
miR-26a	上调	PTEN、PHB、ATM	促进增殖;促血管生成;增强辐射敏感性	[23-25]
miR-21	上调	IGFBP3、FBXO11、VHL、 PDCD4 、hMSH2	诱导肿瘤发生;增强放疗耐受性;预测术后风险	[26-30]

miRNA	变化	相关靶点	功能	参考文献
miR-124	下调	RRAS、NRAS、IQGAP1、ROCK1、 SOS1、CDK4、STAT3、PPP1R13L	抑制肿瘤细胞增殖、迁移侵袭;增加药物敏感性和放疗敏感性;预后	[6-13]
miR-143	下调	NRAS、hexokinase 2	抑制肿瘤细胞增殖、迁移侵袭;增加药物敏感性;抑制糖酵解	[14-15]
miR-128	下调	P70S6K1、E2F3a、BMI1、SP1、 EphB2、SUZ12	抑制增殖和自我更新;诱导凋亡;抑制血管生成;阻滞细胞周期;降低辐射耐受;早期诊断	[16-22]
miR-26a	上调	PTEN、PHB、ATM	促进增殖;促血管生成;增强辐射敏感性	[23-25]
miR-21	上调	IGFBP3、FBXO11、VHL、 PDCD4 、hMSH2	诱导肿瘤发生;增强放疗耐受性;预测术后风险	[26-30]

微小RNA在胶质瘤中的作用及机制研究进展

Research progress on microRNAs in glioma

RichHTML

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 30

相关文章 15

编辑推荐

Metrics

[1]	王蓉, 邢连翔, 黄克亮, 李欣. miR-374靶向下调TRIM35表达可促进乳腺癌细胞增殖和侵袭[J]. 检验医学, 2023, 38(9): 812-817.
[2]	孙泽朋, 王洪彬, 王建东, 宋德伟, 肖鹏. 心肌损伤多肽和蛋白类标志物方法学分析和进展[J]. 检验医学, 2023, 38(8): 784-789.
[3]	陈文举, 周勇, 徐佳佳, 王攀. 血清外泌体miR-23b-3p和miR-4429诊断HCC的价值[J]. 检验医学, 2023, 38(7): 624-628.
[4]	潘信, 吕颖, 李阳, 李荣国. miR-24-3p靶向CHD5影响甲状腺癌细胞迁移能力、侵袭能力和放射敏感性[J]. 检验医学, 2023, 38(7): 640-646.
[5]	王腾飞, 陈珊, 安和兵, 周蕾. 急性白血病患者外周血lncRNA CRNDE、miR-384表达及其临床意义[J]. 检验医学, 2023, 38(7): 686-691.
[6]	张莹, 景丽娟, 李丽. HBV携带者外周血单个核细胞miR-138表达与病毒增殖的关系[J]. 检验医学, 2023, 38(6): 559-562.
[7]	张敏, 王彬宇, 迟伟群, 刘禹. 外泌体非编码RNA作为疾病诊断生物标志物的研究进展[J]. 检验医学, 2023, 38(6): 594-598.
[8]	赵婧, 王佩, 卢丹丹, 齐丹丹, 李轩. 出血性脑卒中患者血清miR-4443、TRAF4相对表达量变化的临床意义[J]. 检验医学, 2023, 38(5): 413-418.
[9]	刘瑞丽, 李兰军, 贾旻蕾, 王一惠, 郝维纳. 胃癌组织miR-7-5p、NOVA2表达与患者临床预后的相关性[J]. 检验医学, 2023, 38(4): 325-329.
[10]	袁爽, 冯磊, 郭小芬, 付小玲, 许静, 刘弘扬. 子宫内膜癌组织miR-433的表达及其与化疗敏感性的关系[J]. 检验医学, 2023, 38(4): 337-341.
[11]	陈哲, 张灵, 刘洁, 王霞, 张斌, 高炳华. 血清miR-326与治疗相关性血液系统恶性肿瘤患者化疗敏感性和预后的关系[J]. 检验医学, 2023, 38(3): 251-256.
[12]	刘冲, 张静, 李胜, 赵奇. miR-335和Fra-1在乳腺癌中的表达及相互关系[J]. 检验医学, 2023, 38(2): 143-147.
[13]	刘庆阳, 袁建明, 夏进军, 姜风英, 王秋波, 王晓明. 基于GEO数据库和临床样本验证CXCL9作为类风湿关节炎生物标志物的研究[J]. 检验医学, 2023, 38(12): 1121-1129.
[14]	周福荣, 李龑杼, 刘勇敢. lncRNA SNP在结直肠癌易感性预测和预后评估中的应用[J]. 检验医学, 2023, 38(12): 1206-1210.
[15]	高建朝, 王思思, 张志生, 张京力, 李晓霞, 马科, 冯志林, 周海丰, 王展海. miR-206、miR-125、miR-21在乳腺癌新辅助化疗疗效和预后评估中的价值[J]. 检验医学, 2023, 38(11): 1062-1068.